[1] Arber DA, Orazi A, Hasserjian R, et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016, 127(20):2391-2405. [2] Itzykson R, Duchmann M, Lucas N, et al.CMML: Clinical and molecular aspects[J]. Int J Hematol,2017,105(6):711-719. [3] Harada Y, Harada H. Rinsho Ketsueki.Chronic myelomonocytic leukemia(CMML): recent advances in molecular pathogenesis and treatment[J]. Rinsho Ketsueki,2016,57(2):147-155. [4] Bacher U, Haferlach T, Schnittger S, et al.Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia[J]. Br J Haematol,2011,153(2):149-167. [5] Such E, Germing U, Malcovati L, et al.Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia[J]. Blood,2013,121(15):3005-3015. [6] Elena C, Gallì A, Such E, et al.Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia[J]. Blood,2016,128(10):1408-1417. [7] Koss MN.Malignant and benign lymphoid lesions of the lung[J]. Ann Diagn Pathol,2004,8(3):167-187. [8] Ahmed S, Siddiqui AK, Rai KR.Low-grade B-cell bronchial associated lymphoid tissue(BALT) lymphoma[J]. Cancer Invest,2002,20(7-8):1059-1068. [9] Wei S, Li X, Qiu X, et al.Primary lung lymphoma involving the superior vena cava[J]. World J Surg Oncol,2012,10:131. [10] Hans CP, Weisenburger DD, Greiner TC, et al.Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J]. Blood,2004,103(1):275-282. [11] 陈光祥, 蔡亮, 张伟, 等. 18F-FDG PET/CT 在淋巴瘤结外侵犯中的诊断价值[J]. 放射学实践,2013,28(1):95-98. [12] Cabanillas F, Rivera N, Pardo WI.Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis[J]. Clin Lymphoma Myeloma Leuk,2016,16(10):550-557. [13] 霍真, 李霁, 刘鸿瑞, 等. 北京协和医院对18年间病理诊断肺淋巴瘤患者的回顾分析[J]. 中华肺部疾病杂志,2016,9(6):600-603. [14] 关炜, 王全师, 吴湖炳, 等. 原发性肠淋巴瘤的18F-FDG PET/CT影像学表现[J]. 南方医科大学学报,2016,36(9):1175-1180. [15] Tamayo P, Martín A, Díaz L, et al.18F-FDG PET/CT in the clinical management of patients with lymphoma[J]. Rev Esp Med Nucl Imagen Mol,2017,36(5):312-321. [16] Saillard C, Guermouche H, Derrieux C, et al.Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma[J]. Hematol Oncol,2017,35(4):864-868. [17] Grignano E, Mekinian A, Braun T, et al.Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and litera-ture review[J]. Leuk Res,2016,47:136-141. [18] Mathew RA, Bennett JM, Liu JJ, et al.Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature[J]. Leuk Res,2012,36(1):72-80. [19] 王媛媛, 沈金辉, 王少洪. 传染性单核细胞增多症淋巴结病临床病理观察[J]. 诊断病理学杂志,2015,22(10):614-616. [20] Toriihara A, Nakajima R, Arai A, et al.Pathogenesis and FDG-PET/CT findings of Epstein-Barr virus-related lymphoid neoplasms[J]. Ann Nucl Med,2017,31(6):425-436. [21] 于亚平, 宋萍, 安志明, 等. 成人非典型传染性单核细胞增多症临床病理特点[J]. 中国实验血液学杂志,2016,24(6):1873-1878. |